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Fluoroquinolone (FQ) resistance is highly prevalent among clinical strains of
Pseudomonas aeruginosa, limiting treatment options. We have reported previously that
highly virulent strains containing the exoU gene of the type III secretion system are more
likely to be FQ-resistant than strains containing the exoS gene, as well as more likely
to acquire resistance-conferring mutations in gyrA/B and parC/E. We hypothesize that
FQ-resistance imposes a lower fitness cost on exoU compared to exoS strains, thus
allowing for better adaptation to the FQ-rich clinical environment. We created isogenic
mutants containing a common FQ-resistance conferring point mutation in parC from
three exoU to three exoS clinical isolates and tested fitness in vitro using head-to-head
competition assays. The mutation differentially affected fitness in the exoU and exoS
strains tested. While the addition of the parC mutation dramatically increased fitness
in one of the exoU strains leaving the other two unaffected, all three exoS strains
displayed a general decrease in fitness. In addition, we found that exoU strains may
be able to compensate for the fitness costs associated with the mutation through better
regulation of supercoiling compared to the exoS strains. These results may provide a
biological explanation for the observed predominance of the virulent exoU genotype in
FQ-resistant clinical subpopulations and represent the first investigation into potential
differences in fitness costs of FQ-resistance that are linked to the virulence genotype of
P. aeruginosa. Understanding the fitness costs of antibiotic resistance and possibilities
of compensation for these costs is essential for the rational development of strategies
to combat the problem of antibiotic resistance.
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INTRODUCTION
Pseudomonas aeruginosa is a Gram-negative pathogen that is the leading cause of nosocomial
pneumonia (Restrepo and Anzueto, 2009; Quartin et al., 2013). Resistance to the fluoroquinolone
(FQ) antibiotics has risen dramatically due to the widespread prescribing of this class of drug,
limiting treatment options for P. aeruginosa infections (Linder et al., 2005). P. aeruginosa acquires
resistance to the FQs through mutations in genes regulating the expression of eﬄux pumps and
through point mutations in target site genes. The target enzymes of the FQs are the type II
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topoisomerases, GyrA/B and ParC/E (Hooper, 2001). Resistance-
conferring mutations in these genes, known as target
site mutations, have been well described in P. aeruginosa
(Nakano et al., 1997; Mouneimné et al., 1999; Higgins et al.,
2003).
Pseudomonas aeruginosa has the ability to cause a variety of
severe infections due to its many virulence factors. Specifically,
P. aeruginosa utilizes the type III secretion system (TTSS) during
acute infections to evade phagocytosis, invade host cells, and
cause cell death (Veesenmeyer et al., 2009). The TTSS consists
of a molecular syringe-like apparatus that extends through the
inner and outer membranes and directly contacts the host cell.
This allows effector toxins (ExoU, ExoS, ExoY, and/or ExoT) to
be directly injected into the cytoplasm of host cells. Although
residing at entirely separate loci, the genes encoding the toxins
ExoU and ExoS are mutually exclusive in most strains, with
the exoS genotype accounting for about 70% of clinical and
environmental strains (Feltman et al., 2001; Garey et al., 2008).
While less prevalent in general, exoU strains are more virulent
than exoS strains, as has been shown in animal models of acute
pneumonia (Shaver and Hauser, 2004). Importantly, infection
with these strains leads to poor outcomes in patients with
ventilator-associated pneumonia (Roy-Burman et al., 2001; El
Solh et al., 2008) as well as increased persistence and severity of
disease (Schulert et al., 2003).
Alarmingly, clinical studies have shown a correlation between
FQ-resistance and virulence. We have previously reported that
patients infected with FQ-resistant strains of P. aeruginosa had
threefold higher mortality or prolonged illness by an additional
5 days compared to those infected with FQ-susceptible strains
(Hsu et al., 2005). In addition, clinical isolates with the more
virulent exoU genotype were shown to more likely be FQ-
resistant than exoS strains (Wong-Beringer et al., 2008; Agnello
and Wong-Beringer, 2012). Others have reported similar results
in isolates from various infection sites (Zhang et al., 2014; Peña
et al., 2015). Furthermore, in a separate study, we found that
the combined traits of FQ-resistance and exoU genotype among
respiratory isolates of P. aeruginosa were significantly associated
with the development of pneumonia rather than bronchitis or
colonization (Sullivan et al., 2014), suggesting that resistance
and virulence traits may be linked, negatively impacting disease
severity.
In a large study of 270 clinical isolates, we found that
significantly more exoU strains were FQ-resistant, compared to
exoS strains (63% vs. 49%, p= 0.03). Sequencing of the FQ target
site genes gyrA/B and parC/E revealed that exoU strains were
more likely than exoS strains to acquire two or more resistance-
conferring target site mutations (Agnello and Wong-Beringer,
2012). Specifically, we found that while FQ-resistant exoU and
exoS strains were similarly likely to possess a mutation in gyrA,
exoU isolates were more likely to also have acquired an additional
mutation in parC, resulting in greatly increased levels of
resistance. While there is mounting evidence for the co-selection
of resistance and virulence traits among pathogenic bacteria
(Beceiro et al., 2013), the biological mechanisms underlying these
observations are not well understood. Since the identification of
the ExoU and ExoS toxins of the P. aeruginosa type III secretion
system, many studies have investigated the roles of each toxin
during infection (Allewelt et al., 2000; Schulert et al., 2003;
Shaver and Hauser, 2004, 2006) while others have described the
association of exoU strains with increased FQ resistance (Lakkis
and Fleiszig, 2001; Maatallah et al., 2011) supporting our own
observations. The aim of the current study was to gain insights
into the biological basis underlying the differential development
of resistance in exoU vs. exoS strains, which previous studies have
not explored. We hypothesize that the greater propensity of exoU
strains to acquire multiple target site mutations compared to exoS
strains reflects a difference in the fitness costs associated with FQ-
resistance mutations, favoring the strains with the exoU genetic
background.
A recent meta-analysis of studies conducted on fitness costs of
resistance to a variety of antibiotic classes in different organisms
showed that most point mutations are generally costly (Melnyk
et al., 2015). However, there is great variability depending on
organism, drug, and mechanism of resistance. Furthermore,
fitness costs can be mitigated through the accumulation of
compensatory mutations that restore fitness to wild-type levels
without loss of resistance (Andersson and Hughes, 2010). FQ-
conferring mutations have been shown to impose variable fitness
costs, depending on strain background and specific combinations
of mutations (Komp Lindgren et al., 2005; Luo et al., 2005;
Marcusson et al., 2009; Machuca et al., 2014; Wasels et al.,
2015).
In the current study, we compared the fitness effects of a
target site mutation in parC using isogenic mutants created
from clinical exoU and exoS isolates. We investigated the
fitness effects of this mutation using in vitro head-to-head
competition experiments. Changes in supercoiling level and
mutation frequency between mutants and parent strains were
also assessed to explore potential mechanisms for the difference
in fitness observed.
Our results suggest that the FQ resistance-conferring point
mutation in parC studied here may confer less of a fitness
cost to exoU strains than to exoS strains, with exoU strains
showing evidence of compensation for the fitness costs.
These results provide a potential biological explanation for
the observed predominance of exoU strains in the clinical
FQ-resistant population. The co-selection of FQ-resistance in
highly virulent exoU strains will likely have a negative impact
on patient outcomes, which underscores the importance to
gain a better understanding of the biological basis for this
observation.
MATERIALS AND METHODS
Ethics Statement
The institutional review boards at both Huntington Hospital
and the University of Southern California have approved this
study. Informed consent was waived from all participants
since bacteria cultures were saved as part of a longitudinal
epidemiological surveillance study. All data from respiratory
cultures were analyzed anonymously to protect patient
privacy.
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TABLE 1 | Characteristics of Strains.
Name LVXa MIC
(µg/ml)
LVX + EPIb
MIC (µg/ml)
Amino Acid
Change
Doubling Time, h
(−/+ SEM)c
exoU U-37 16 0.5 GyrA: T83I 2.0 (1.7–2.4)
U-37PC∗ 16 0.5 GyrA: T83I
ParC: S87L
1.7 (1.5–1.9)
U-91 2 2 GyrA: T83I 3.9 (3.78–3.93)
U-91PC∗ 16 2 GyrA: T83I
ParC: S87L
3.9 (3.87–3.96)
U-92 16 0.5 GyrA: T83I 2.5 (2.3–2.7)
U-92PC∗ 16 0.5 GyrA: T83I
ParC: S87L
2.8 (2.6–3.0)
exoS S-139 4 0.5 GyrA: T83I 3.4 (3.3–3.6)
S-139PC∗ 32 0.25 GyrA: T83I
ParC: S87L
3.1 (2.9–3.3)
S-247 16 1 GyrA: T83I 2.5 (2.4–2.6)
S-247PC∗ 16 8 GyrA: T83I
ParC: S87L
2.5 (2.4–2.7)
S-215 16 1 GyrA: T83I 2.4 (2.2–2.7)
S-215PC∗ 16 1 GyrA: T83I
ParC: S87L
2.3 (2.2–2.5)
Mutants with Ser87Leu substitution in ParC denoted PC∗. aLVX, Levofloxacin;
bEPI, efflux pump inhibitor; cDoubling time during exponential phase.
Bacterial Strains and Culture Conditions
Strains of P. aeruginosa used in this study (Table 1) were selected
from a collection of isolates obtained from the respiratory tract
of hospitalized patients at Huntington Hospital, Pasadena, CA,
USA from 2005 to 2009 and were stored in cryovials at −80◦C
in 30% glycerol. All strains had been previously characterized for:
the presence of the exoU or exoS gene, resistance to levofloxacin,
presence of mutations in the quinolone-resistance determining
regions of gyrA/B and parC/E, and clonal relatedness by RAPD
PCR, as described in Agnello and Wong-Beringer (2012). Strains
were routinely grown as 5 ml cultures in Luria-Bertani (LB) broth
in 12 ml polypropylene culture tubes at 37◦C and shaking at
250 rpm for liquid culture, or grown on Pseudomonas Isolation
Agar (PIA) plates at 37◦C. Strains were routinely sub-cultured
twice after inoculation from the frozen stock by 1:100 dilution
(vol:vol) before use in any experiment.
Susceptibility Testing and Sequencing
Susceptibility testing to levofloxacin and rifampicin was
performed by broth microdilution in twofold dilutions at
concentrations ranging from 0.25 to 128 µg/ml according to
guidelines recommended by CLSI (Clinical and Laboratory
Standards Institute, 2007). In order to assess the involvement
of the multidrug Mex eﬄux pumps to resistance, MIC of
levofloxacin was also measured with the addition of an
eﬄux pump inhibitor (EPI, MC-0228; Sigma) at 20 µg/ml
(Kriengkauykiat et al., 2005).
For sequencing, genomic DNA was extracted and purified
from isolates using the DNeasy Mini Kit (Qiagen). The
quinolone-resistance determining regions of target genes gyrA,
gyrB, parC, and parE were amplified by PCR using previously
published primers and conditions and sequenced to identify
mutations compared to wild-type strain PAO1 (Table 2) (Jalal
and Wretlind, 1998; Lee et al., 2005; Winsor et al., 2011).
Creation of Target Site Mutants
Since most FQ-resistant isolates have gyrA mutations, three
exoU and three exoS isolates with a pre-existing gyrA FQ-
resistance mutation (Thr83→Ile substitution) were selected
for mutagenesis. A site-directed point mutation in the parC
gene leading to the amino acid substitution Ser87→Leu was
introduced via electroporation of an oligonucleotide in order to
create isogenic mutants, using the technique of oligonucleotide
recombination as described previously (Swingle et al., 2010;
Agnello and Wong-Beringer, 2014). Briefly, a single-stranded
oligonucleotide 60 bases in length was designed using the parC
gene sequence of reference strain PAO1 (Winsor et al., 2011)
(Table 2). The oligo is identical to the PAO1 sequence from
nucleotides 230 to 289, save for the point mutation TCG→TTG
at location 31 of the oligo, corresponding to nucleotide 260 in the
parC gene. This point mutation, which is the most common parC
mutation observed among fluoroquinolone-resistant clinical
strains, gives rise to the Ser87→Leu amino acid change in the
ParC protein.
Strains were made electro-competent by several washes with
300 mM sucrose solution as described in Choi et al. (2006)
and transformed by electroporation at 2.5 kV in a 0.2 cm
cuvette using a Micropulser (Bio-Rad, Hercules, CA, USA).
SOC medium (1 ml) was immediately added and the cells
were outgrown overnight at 37◦C on PIA plus levofloxacin at
concentrations two and fourfold above the original minimum
inhibitory concentration (MIC) of the isolates for selection.
Single colonies were collected and the parC gene was sequenced
as described above to confirm that recombination had occurred.
Growth Rate Measurements
Independent overnight cultures were diluted to OD600 ∼0.1 and
grown at 37◦C with shaking in 50 ml LB broth in a 100 ml flask.
An aliquot of the culture (150 µl) was sampled every 30 min for
8 h and turbidity was measured at OD600 using a Tecan Sunrise
microplate reader (Tecan Group Ltd., Switzerland). Results were
reported as an average of at least three independent experiments
in terms of doubling time per hour.
Insertion of Fluorescent Tag
Mini-Tn7 vectors developed and generously shared with us
by Dr. Herbert Schweizer (Choi et al., 2005) were utilized to
insert cassettes containing the genes encoding YFP or CFP
as well as a cassette containing the lux operon into strains
used for competition experiments and supercoiling experiments,
respectively. The cassette inserts into the P. aeruginosa genome
at a single location (attTn7 site downstream of the glmS
gene) and contains the gene for the fluorescent protein under
the control of a constitutive promoter or the lux operon
under the control of a supercoiling-sensitive promoter (Moir
et al., 2007), as well as a gentamicin-resistance marker for
selection. The delivery plasmid was co-electroporated with a
helper plasmid (pTNS3) encoding the necessary transposase
function for insertion. The electroporation protocol used for
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TABLE 2 | Genetic elements used.
Sequence Reference
Primer name PCR
glmS-up CTGTGCGACTGCTGGAGCTGA Choi and Schweizer, 2006
glmS-down GCACATCGGCGACGTGCTCTC Choi and Schweizer, 2006
Tn7-R CACAGCATAACTGGACTGATTTC Choi and Schweizer, 2006
Tn7-L ATTAGCTTACGACGCTACACC Choi and Schweizer, 2006
Oligo for recombination
PC∗ TGCTCGGCAAGTTCCACCCGCACGGCGACTTGGCCTGCTA
CGAGGCCATGGTGCTGATGG
Agnello and Wong-Beringer, 2012
Plasmid Function References
pTNS3 Helper plasmid, encodes Tn-7 transposition pathway Choi et al., 2005
pUC18T-mini-Tn7T-Gm-eyfp Delivery plasmid for GmR marker and YFP Choi and Schweizer, 2006
pUC18T-mini-Tn7T-Gm-ecfp Delivery plasmid for GmR marker and CFP Choi and Schweizer, 2006
TOP10/mini-Tn7-PA0614 promoter-Gm-luxCDABE Delivery plasmid for GmR marker and lux operon Choi and Schweizer, 2006
transformation is described in detail in Choi and Schweizer
(2006); briefly, strains were made electro-competent through
a series of washes with 300 mM sucrose, subjected to
electroporation as described above, and plated on LB plates
containing 30 µg/ml gentamicin for selection. To confirm
insertion had occurred, PCR was performed to amplify the
insertion region using primers listed in Table 2 and protocol
as previously described (Choi and Schweizer, 2006) (data not
shown).
In vitro Competition Assays
To investigate the effects of the parC mutation (PC∗) on fitness,
mutants were directly competed against isogenic parent strains
in co-culture. Strains were tagged with either CFP or YFP for
differentiation as described above. PC∗ mutant strains were
initially tagged with CFP, and competed against the respective
isogenic parent strain tagged with YFP. To confirm neutrality of
the tags, experiments were also performed with YFP-mutants and
CFP-parents.
Strains were grown overnight in LB, and 105 CFU of each
strain was co-inoculated into 10 ml LB in a 50 ml flask, and
grown with shaking at 37◦C. Every 24 h, 10 µl of the culture
was transferred to a new flask containing 10 ml fresh LB,
and a sample of the culture was serially diluted then plated
on PIA for CFU enumeration. Colonies of each color were
counted using a fluorescent wide-field microscope (Zeiss Axio
Zoom.V16). Experiment duration ranged from 4 to 7 days.
The ratio of the number of CFUs of the mutant-to-parent
strain on each day of the experiment was calculated and used
to determine the relative fitness of the mutant. Experiments
were repeated a minimum of five times. Assays were also
performed with the addition of levofloxacin equal to 1/8 the
MIC (2 or 0.5 µg/ml). At day 7 of each competition experiment,
colonies were selected from plates, inoculated into LB, grown
overnight, and stored at −80◦C in 30% glycerol until ready for
use in subsequent experiments. These were described as ‘aged’
strains. Aged strains were subjected to a secondary competition
experiment vs. the original strains. Secondary competition with
aged strains was performed as described above, and lasted for
4 days.
Supercoiling Assay
We adapted a reporter assay to estimate the ability to maintain
supercoiling levels in mutants compared to parent strains by
inserting a Tn7 cassette containing the lux operon under the
control of a supercoiling-sensitive P. aeruginosa promoter from
the gene PA0614 (Moir et al., 2007). The cassette was inserted
as described above. Luminescent strains were grown to mid-
exponential phase, then diluted 1:4 in LB+ levofloxacin at 1/4,
1/2, and 1x the measured MIC, and grown in triplicate in a deep
well 96-well plate for 7 h. Luminescence was measured using
the Envision Multi-Label plate reader (Perkin-Elmer) as well as
OD600 as described above. Relative Luminescence Units (RLU)
was normalized to OD600 for all comparisons.
Mutation Frequency Assay
Mutation frequency was estimated during competition
experiments using the spontaneous rifampicin resistance
method (Oliver et al., 2000). At each 24-h interval, competition
cultures were plated on PIA+ rifampicin at 5x the MIC (ranging
from 40 to 500 µg/ml depending on the strain) in addition to
plating on PIA. The mutation frequency reported is the number
of colonies that grew on PIA + rifampicin after 48 h divided
by the number of colonies on PIA alone. Colonies of each
strain were differentiated and counted based on fluorescence
as described above. For strain 139, 5x the MIC of rifampicin
corresponds to 500 µg/ml, which turned the plates a dark shade
of red and prevented the differentiation of the fluorescence of the
colonies. Thus, for this strain, each rifampicin-containing plate
was replica-plated using sterile velvets onto a fresh PIA plate and
incubated for an additional 24 h before colonies were counted.
Statistical Analysis
GraphPad Prism v.6 (GraphPad.com, San Diego, CA, USA)
was used to perform statistical analysis. ANOVA was used to
compare continuous variables where appropriate, and student’s
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t-test was used to compare mean ratios to the null hypothesis of 1
(indicating no difference). A p value ≤ 0.05 denotes significance.
RESULTS
We previously created isogenic mutants from 6 clinical isolates
of P. aeruginosa (three exoU and three exoS) by inserting a
point mutation commonly observed in fluoroquinolone-resistant
isolates into the parC gene (Agnello and Wong-Beringer,
2012). The goal of the current study was to investigate the
biological effects of this target site mutation in a controlled
genetic background. Mutants are denoted PC∗. Interestingly,
the addition of the parC mutation increased the levofloxacin
MIC in only two of the six isolates. Characteristics of mutant
and parent strains used in this study are summarized in
Table 1.
Growth Rate in Monoculture
As an initial comparison of the relative fitness of mutant vs.
parent strains, we tested the doubling time in independent
cultures by measuring optical density every 30 min over an 8-
h period; results are an average of at least three independent
experiments (Table 1). Doubling time during exponential phase
was calculated by dividing the time interval over the number of
generations. Growth rates of all six mutants were comparable to
parent strains.
parC Mutation Differentially Affects
Competitive Fitness of exoU vs. exoS
Strains
To investigate the fitness costs of the parC mutation, we
performed head-to-head competition assays. Each PC∗ mutant
was directly competed against its isogenic parent strain by
growth in co-culture for 4 days. Because the strains competed
are identical save for the point mutation, any fitness cost is
attributable to the mutation. In each individual competition
experiment, one strain is tagged with CFP (cyan fluorescent
protein), and the other with YFP (yellow fluorescent protein).
This allows for the direct enumeration of the number of colonies
of each strain after serial dilution onto agar plates. Colonies were
counted every 24 h, and the relative fitness of the mutant is
determined from the ratio of mutant-to-parent CFU/ml. Each
experiment was independently repeated at least five times. We
confirmed the neutrality of the YFP and CFP tags by repeating
each experiment with each strain carrying the opposite tag. No
difference was found, and therefore results from all experiments
were combined.
Figure 1 shows the average mutant-to-parent ratios over
time for each strain. Each strain has a unique pattern of fitness
costs associated with this mutation; however, in general, there
appears to be a higher fitness cost for the exoS strains. The exoS
strains S-139PC∗, S-247PC∗, and S-215PC∗ show a consistent
fitness defect over all time points, with strain S-139PC∗ the
most affected. On the other hand, strain U-92 has the smallest
fitness effect, with the mutant/parent ratios ranging from 1.2 to
2.0 over 2–4 days of competition. Strain U-37 shows a similar
pattern except the mutant starts with lower fitness (ratio 0.5
at day 2), but catches up to the parent strain by day 4 with
a ratio of 0.99. Strain U-91 is unique and interestingly shows
a striking increase in fitness due to the mutation; the mutant
rapidly outcompetes the parent strain and completely takes over
the culture by day 3.
exoU-PC∗ Mutants can Better Maintain
Wild-Type Supercoiling Levels than
exoS-PC∗ Mutants
We assessed supercoiling of parent vs. mutants in exoU strains
U-92 and U-37 and exoS strains S-215 and S-139 by inserting a
Tn7 genetic element in which a supercoiling sensitive promoter
controls the lux operon (Moir et al., 2007). Due to challenges
inserting the reporter, only two strains of each background were
chosen as representative strains. Strains with the insertion were
grown under levels of levofloxacin at and below the MIC in order
to maximally induce expression of the reporter, and luminescence
values were normalized to OD600. We measured the level of
luminescence in the parent strain as an indirect reporter of the
baseline level of supercoiling; any difference in luminescence
expression for the PC∗ strain reflects a change in supercoiling
due to the parC mutation. Results show that the PC∗ mutants in
general have decreased luminescence compared to parent strains;
however, this decrease was significantly more pronounced in
exoS-PC*∗ strains (Figure 2), suggesting that exoS strains with the
PC∗ mutation are somehow less able to maintain the supercoiling
level of the parent strains, which may have negative effects
on fitness. This is surprising given that the primary role of
topoisomerase IV (ParC) is decatenation of daughter replicons
and not regulation of supercoiling (Hooper, 2001); however, in
this context it may suggest an overall difference in supercoiling
regulation in exoU vs. exoS strains.
Analysis of Aged Strains
Because, we observed that the fitness of exoU-PC∗ mutants
tended to increase after 24 h of competition, we investigated
whether stable changes were occurring during competition that
allowed the strains to compensate for fitness costs associated
with the parC mutation. We collected colonies of parent and
PC∗ strains from a primary competition experiment (parent
vs. mutant) after 7 days and labeled these ‘aged’ strains. In
addition, we investigated the effect of sub-inhibitory levels of
fluoroquinolone exposure on competitive fitness and ability
to compensate for fitness costs by collecting aged strains
from primary competition experiments in which 1/8 MIC of
levofloxacin was added to the media.
We were not able to collect aged colonies from the primary
competition experiments of strain 91 due to the vast difference
in fitness between the PC∗ mutant and parent strains; the PC∗
strain completely overtook the culture by day 3. Because this left
us with only two exoU strains (U-92 and U-37), we chose two
exoS strains in order to have an equal number in each group
for comparison. We chose strains 215 and 139 because these
represent both ends of the spectrum in terms of fitness of the PC∗
mutants in vitro; strain S-215PC∗ shows the least fitness cost of
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FIGURE 1 | In vitro fitness of exoU and exoS-PC∗ mutants. The average log10 CFU/ml ratio of PC∗ vs. parent strains per day of in vitro competition are shown.
Ratios above zero indicate the mutant is more fit, while ratios below zero indicate a fitness cost. The ratio for exoS strains generally decreases over the course of the
experiment, while the ratios for exoU strains either increases or remains stable. Results are an average of at least five independent experiments. Error bars = SEM.
For strain U-91, the dotted line and circles indicate ratios after day 2 are beyond the limit of detection. ∗ Indicates the PC∗/parent CFU ratio is significantly different
than 1 at p < 0.05.
FIGURE 2 | Supercoiling changes in PC∗ mutants compared to parent strains. Each strain contains a chromosomal reporter construct in which the lux operon
is under the control of a supercoiling-sensitive promoter. Strains were grown in concentrations of levofloxacin equal to 1/4, 1/2, and 1x the MIC. Luminescence was
normalized to cell count using OD600. Results are an average of three independent experiments, and error bars represent SEM. ∗p < 0.05; ∗∗p < 0.01.
all the exoS strains, while strain S-139PC∗ exhibits the greatest
fitness cost.
Sequencing the FQ-target site genes of the aged strains
revealed that no changes occurred in the genes associated
with FQ-resistance except for exoU strain U-92, in which
the parent acquired the Ser87Leu substitution in ParC during
competition under levofloxacin exposure (+LVX) at 1/8 MIC.
All PC∗ strains maintained the parC mutation. The MIC to
levofloxacin did not change in any of the aged strains (data not
shown).
Aged PC∗ Mutant exoU vs. exoS Strains
Show Dramatic Difference in Fitness
To investigate whether the aged strains had acquired adaptations
during competition that rendered them more fit, we compared
the fitness of each aged strain to its un-aged counterpart. Aged
strains were subjected to a secondary competition experiment
in which they were competed against the original, un-aged
strain that contained the opposite fluorescent tag, enabling
the discrimination and enumeration of each strain during
competition. Results reflect the aged-to-un-aged ratio at Day
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2 (Figure 3). Because each aged strain was competed directly
against an un-aged version of itself, we were able to directly
observe if fitness had changed in the aged strains. All parent
strains had a negligible change in fitness. Both exoU-PC∗ aged
strains increased in fitness greater than fourfold, while the exoS-
PC∗ aged strains showed a 50% decrease in fitness; S-139PC∗ was
greater than 100 times less fit than before aging.
We also investigated whether growth under sub-inhibitory
levels of levofloxacin affected fitness, and if mechanisms to
compensate for fitness costs evolved under these conditions. The
addition of levofloxacin did not affect the results of primary
competition experiments (data not shown), but notable results
were seen in the secondary competition experiments of the
aged vs. un-aged strains, which also included 1/8 MIC of
levofloxacin. Upon subsequent exposure to the drug, exoU-PC∗
strains were much more fit, outcompeting the un-aged strain
rapidly. Specifically, the aged PC∗ mutants of exoU strains U-
37 and U-92 outcompeted the un-aged strains significantly and
rapidly, much more so than in the competition experiments
without the drug. Interestingly, the measured MICs of the aged
and un-aged strains remain unchanged. exoS-PC∗ strains showed
conflicting results; S-215PC∗ had gained fitness, while S-139PC∗
had slightly decreased fitness (Figure 3).
Mutation Frequency
Compensation for potential fitness costs of a resistance-
conferring mutation can evolve through the accumulation of
beneficial mutations. Therefore, we investigated whether the rate
of spontaneous mutation frequency could explain the increase
in fitness during competition that was seen in exoU-PC∗ strains.
Mutation frequency was estimated by calculating the frequency
of spontaneous resistance to rifampicin (RifR) (Oliver et al.,
2000). We estimated mutation frequency during the primary
competition experiments for exoU strains U-92 and U-37, and
exoS strains S-215 and S-139 by plating the mixed competition
culture on agar containing 5x the MIC of rifampicin at each
time point (Days 1–7), and counting the number of colonies
based on fluorescence of each strain that were able to grow on
the rifampicin-containing plates compared to the overall CFU
counts. At Day 7, the exoU-PC∗ strains have both a higher
mutation frequency than the parent strains as well as a higher
mutation frequency compared to Day 1. exoS strain S-215PC∗
had a lower frequency at Day 7 compared to its parent strain
as well as a lower frequency compared to Day 1. Surprisingly,
exoS strain S-139PC∗, which is significantly less fit than its
parent strain, has a twofold higher mutation frequency than the
parent strain at Day 7. However, its mutation frequency at Day
7 decreased almost threefold from Day 1 (Figure 4). Therefore,
mutation frequencies seem to generally correlate with fitness
results.
DISCUSSION
Pseudomonas aeruginosa is considered one of six bacteria that
pose an immediate threat to public health, according to the
Infectious Diseases Society of America, due to its increasing
prevalence, broad arsenal of virulence factors, and emergence
of resistance to all available antibiotics (Boucher et al., 2009).
In its recent report entitled “Antibiotic Resistance Threats in
the United States” the Centers for Disease Control named
P. aeruginosa a serious threat that requires prompt action
and continual monitoring to prevent a worsening of the
problem of resistance (Centers for Disease Control [CDC], 2013).
Notably, resistance rates of P. aeruginosa to the once-effective
fluoroquinolone (FQ) antibiotics are now greater than 30% in
the United States, with many of those strains also multi-drug
resistant (Rosenthal et al., 2012).
FIGURE 3 | Fitness of aged strains. Strains were collected at the end of a 7-day primary competition experiment (PC∗ vs. parent) with and without the addition of
sub-inhibitory concentration of levofloxacin (+LVX) and subsequently re-competed in a secondary competition experiment (aged vs. un-aged) with or without
levofloxacin at the same concentration. Results shown reflect the average fitness of aged strains after 48 h of competition. Experiments were performed in duplicate.
Error bars = SEM.
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FIGURE 4 | Mutation frequency of PC∗ mutants vs. parent strains
measured during competition experiments. The frequency of
spontaneous rifampicin resistance was used to estimate mutation frequency
at each time point during a 7-day competition experiment. Bars represent fold
difference of the PC∗ vs. parent at Day 7 and the fold difference at Day 7 vs.
Day 1 for each PC∗ strain. Error bars = SEM. ∗p < 0.05; ∗∗p < 0.01.
During acute disease, P. aeruginosa utilizes the toxins of
the type III secretion system to circumvent the host immune
system and establish infection. Of the four exotoxins, exoU is the
most virulent, encoding a potent phospholipase that disrupts the
plasma membrane and leads to rapid cell death (Sato et al., 2003).
ExoU activity induces excessive inflammation and tissue damage
in the host as well as increased bacterial dissemination that can
lead to septic shock (Kurahashi et al., 1999) and higher rates
of mortality compared to infections with ExoS-secreting strains
(Shaver and Hauser, 2004; Zhang et al., 2014; Peña et al., 2015).
As the problem of antibiotic resistance continues to worsen, it
is becoming apparent that the evolution of virulence factors and
antibiotic resistance cannot be considered strictly independent
processes (Beceiro et al., 2013; Hauser, 2014). Previously,
we found that infection by FQ-resistant P. aeruginosa was
an independent predictor for threefold higher mortality or
prolonged illness by an additional 5 days compared to those
infected with FQ-susceptible strains (Hsu et al., 2005). In a
separate study, we reported that among patients from whom
P. aeruginosa was isolated from the respiratory tract, strains with
the combined traits of exoU and FQ-resistance were much more
likely to cause pneumonia than exoS, FQ-resistant strains or
either trait alone (Sullivan et al., 2014).
Analysis of 270 of our P. aeruginosa clinical isolates led to
the observation that exoU strains are not only enriched in the
FQ resistant sub-population, but are also more likely to have
acquired two or more target site mutations than exoS strains,
especially in the parC gene (Agnello and Wong-Beringer, 2012).
In order to study the biological effects of a resistance-conferring
mutation in a controlled, isogenic background, we adapted a
technique for inserting point mutations into bacterial genomes
for use in our clinical isolates (Swingle et al., 2010). Using
the technique of oligonucleotide recombination, we created 6
FQ-resistant mutants (three exoU and three exoS) (Agnello
and Wong-Beringer, 2014) from clinical strains by inserting a
mutation into the parC gene.
Because the target site mutation, we inserted in parC rarely
occurs in clinical isolates without a pre-existing mutation in gyrA
(Jalal and Wretlind, 1998), we chose clinical strains that had a
pre-existing gyrA mutation (Thr83Ile) in order to mimic FQ-
resistant strains encountered in the clinical setting. These specific
point mutations in gyrA and parC are commonly found in FQ-
resistant clinical strains of P. aeruginosa (Nakano et al., 1997;
Mouneimné et al., 1999; Higgins et al., 2003; Agnello and Wong-
Beringer, 2012). The goal of the current study was to assess the
biological effects on fitness of the parC mutation and determine
if the magnitude of the effects differ in exoU vs. exoS strains.
The acquisition of resistance is generally thought to be
accompanied by a fitness cost to the bacterium (Andersson
and Levin, 1999); however, there are many reports of neutral
fitness effects or enhanced fitness due to resistance-conferring
mutations. Evidence from FQ-resistant E. coli, S. pneumoniae,
and N. gonorrhoeae suggest that a secondary resistance mutation
does not further decrease fitness and may restore the low fitness
of primary mutants back to wild-type levels (Komp Lindgren
et al., 2005; Rozen et al., 2007; Marcusson et al., 2009; Kunz
et al., 2012; Machuca et al., 2014). Furthermore, many fitness
effects seem to be strain dependent, as was shown in a study
of ciprofloxacin-resistant Campylobacter jejuni, in which a gyrA
mutation conferred a high cost to one strain but actually
increased fitness for a different strain (Luo et al., 2005). Similar
results were seen in S. pneumoniae, in which some FQ-resistant
mutant strains had increased fitness while others had a significant
cost (Balsalobre and de la Campa, 2008). This suggests that fitness
effects are highly dependent on strain genetic background, which
may explain the differences, we have seen between exoU and exoS
strains.
Head-to-head competition assays are a standard method for
investigating the relative fitness of a mutant strain compared
to its isogenic parent strain, and it is possible to detect
differences in fitness as small as 1% (Andersson and Levin, 1999;
Corzett et al., 2013). Strains are mixed together in co-culture,
and must compete for the limited available resources (Finkel,
2006; Kraigsley and Finkel, 2009). In most studies, strains are
differentiated based on selective growth on antibiotic plates.
However, since the parC mutation, we inserted did not increase
the levofloxacin MIC in all strains, we had to develop a different
approach. We took advantage of a Tn7-based system developed
by Schweizer (Choi et al., 2005) in order to insert a cassette
containing either YFP or CFP under the control of a strong
promoter.
The growth of the PC∗ strains did not differ dramatically
from those of the parents when grown in monoculture; however,
differences were seen when strains had to compete for resources
in the same culture flask during competition experiments.
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Overall, the parC mutation imposed a moderate to considerable
fitness cost on exoS strains, while exoU strains were able
to better tolerate the mutation. Notably, fitness of exoU-PC∗
strains ranged from maintaining the wild-type level of fitness to
outcompeting the parent strain by more than 10-fold, whereas
exoS-PC∗ strains were consistently less fit than parent strains.
The FQ target site mutation investigated in the current study
occurs in a topoisomerase enzyme and therefore may have an
effect on the regulation of supercoiling. Common methods for
investigating supercoiling levels rely on reporter plasmids that
need to be selected for and maintained. Because, we are using
clinical isolates, there is a high level of multi-drug resistance
that precludes the use of standard selection antibiotics. To
circumvent this, we inserted a Tn7 element (Moir et al., 2007)
onto the chromosome in which a supercoiling sensitive promoter
controls lux expression. exoU-PC∗ mutants were better able to
maintain the supercoiling levels of the parent strains, while exoS-
PC∗ mutants showed a more drastic change in supercoiling, as
observed by decreased lux expression. Other studies have shown
that changes in supercoiling are correlated with changes in fitness
(Kugelberg et al., 2005; Marcusson et al., 2009), and therefore the
regulation of supercoiling may reflect the level of overall fitness
and may explain the fitness differences seen in our strains. The
ability of exoU-PC∗ strains to better regulate supercoiling levels
under the stress of FQ exposure reflects increased fitness of these
strains overall. The supercoiling level of the cell affects global gene
expression and replication efficiency, and changes in supercoiling
may alter response to environmental stressors, or even modulate
pathogenesis in the host (Redgrave et al., 2014).
In the primary competition experiments, exoU-PC∗ mutants
tended to increase in fitness over the course of the 4-day
experiment. This suggests that exoU strains may be acquiring
beneficial adaptations that allow for the compensation of the
fitness costs associated with the PC∗ mutation. Bacteria have
the ability to rapidly evolve compensatory mechanisms to
mitigate the fitness costs associated with antibiotic resistance,
and compensatory mechanisms can reverse fitness costs without
any loss of resistance (Andersson and Hughes, 2010). The exoU-
PC∗ strains that had been ‘aged’ through a primary competition
experiment for 7 days have increased fitness compared to the un-
aged strains, while aged exoS-PC∗ strains have decreased fitness.
The results suggest that the compensatory mechanisms in exoU
strains most likely are acting as a repressor of the negative fitness
effects of the parC mutation, as opposed to just conferring a
general gain in fitness, based on the observation that the aged
parent strains did not show as much of an increase in fitness as the
PC∗ mutants. The observed ability of exoU strains to compensate
for the costs of FQ-resistance has many clinically negative
consequences. Compensation in clinical populations leads to the
stabilization of resistant populations without the presence of drug
(Andersson and Hughes, 2010). Increased fitness after acquisition
of FQ-resistance adds to the already complicated problem of
treating infections caused by highly virulent exoU strains.
The inability of exoS-PC∗ strains to regulate supercoiling
suggests that the compensatory mechanisms in exoU strains
are acting to maintain wild-type supercoiling levels in the PC∗
mutants, as has been reported in other studies of compensation
of the costs of FQ-resistance (Kugelberg et al., 2005; Marcusson
et al., 2009). Although, we did not identify the exact mechanisms
responsible for the compensatory effects, we have shown that
they are stable since strains were frozen and grown before
testing for compensation in secondary competition experiments,
and the results were reproducible in repeated experiments.
Sequencing of the quinolone-resistance determining regions
of gyrA/B and parC/E revealed no additional mutations had
occurred during competition; however, beneficial mutations may
have occurred elsewhere. For both exoU strains tested, the
mutation frequencies correlated with the increase in fitness
observed during competition experiments, suggesting that higher
mutation frequency may facilitate the acquisition of beneficial
mutations that mitigate the fitness costs of the parC mutation.
A dramatic increase in fitness occurred in the aged exoU-PC∗
strains taken from a primary competition experiment in which
sub-inhibitory levels (1/8 the MIC) of levofloxacin were added
to culture. Although this low level of drug did not affect the
growth of strains in the primary competition experiment, when
the aged exoU-PC∗ strains were re-competed under the same
concentration of levofloxacin, they were 20–100 times more fit
than before aging. In contrast, exoS-PC∗ strains were dramatically
less fit under these circumstances. However, none of the aged PC∗
strains had an increase in MIC, nor any additional FQ-resistance
mutations in target site genes. These results suggest that although
the level of levofloxacin was much below the MIC, highly fit
strains were selected for rapidly, more so than in conditions
without drug. Also, the highly fit strains were not more resistant,
suggesting that perhaps the presence of levofloxacin accelerated
the process of compensation for the already present resistance
mutations. As sub-inhibitory concentrations of antibiotics are
routinely present during treatment due to insufficient dosing or
inadequate penetration to certain areas of the body (Baquero
and Negri, 1997; Andersson and Hughes, 2014), the implications
of our results are alarming and suggest that low levels of
antibiotic can rapidly select for highly fit strains, preferentially
the highly virulent exoU-containing strains. Furthermore, when
these highly fit, highly virulent strains are re-introduced to
the antibiotic, they will rapidly outcompete all other strains.
The sub-inhibitory concentration was also able to select for
a parC mutation in an exoU parent strain, emphasizing the
known phenomenon that selection for resistance mutations can
occur at sub-inhibitory levels of antibiotic (Baquero et al., 1998;
Andersson and Levin, 1999; Gullberg et al., 2011; Andersson and
Hughes, 2014).
Overall, these results suggest a potentially lower fitness burden
associated with FQ-resistance for exoU strains than for exoS
strains, which in part provides an initial biological explanation
for exoU strains’ greater tendency to acquire FQ-resistance
in the clinical setting. Although, we have yet to identify the
specific genetic components underlying the fitness differences,
we suspect that genes unique to strains with the exoU genetic
background may contribute to the fitness benefits seen in this
study. The P. aeruginosa genome consists of a highly conserved
core genome, but variability is introduced in the form of genomic
islands, which make up the accessory genome. Genes within
the islands usually encode accessory activities such as specific
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pathogenicity or symbiosis factors (Harrison et al., 2010). The
exoU gene, along with its chaperone spcU, is located on a
pathogenicity island, a specialized genomic island. exoU has been
identified as part of a few different pathogenicity islands. The
most highly studied is from the reference strain PA14, in which
the exoU gene is on an island named PAPI-2 (Kulasekara et al.,
2006). Studies with PA14 have shown that virulence is dependent
on the presence of the entire island and not just the exoU gene
alone; therefore, other as yet unknown genes contained on the
pathogenicity islands contribute combinatorially to the increased
virulence of exoU strains (Harrison et al., 2010). Furthermore,
pathogenicity in strain PA14 requires the coordinated action of
multiple virulence factors, associated with both the core and
accessory genomes (Lee et al., 2006). Therefore, it is possible
that other genes in the accessory genome in combination with
exoU may provide fitness benefits to exoU strains that allow for
increased ability to adapt to the fitness costs of FQ-resistance.
Genomic islands have been shown to confer fitness benefits, and
the accessory genome of P. aeruginosa is an important driver
of the ability of strains to persist in a particular environment
(Hacker and Carniel, 2001; Ozer et al., 2014).
This study has several limitations. We acknowledge that a
limited number of clinical strains and their isogenic mutants
were evaluated in the study. Despite having access to a large
collection of clinical strains, the selection of strains to create
isogenic target site mutants to study the effect of FQ-resistance
on fitness proved challenging, as most of the isolates in
our collection were found to already contain the resistance-
conferring mutation that, we are investigating, due to the high
prevalence of FQ resistance in clinical isolates of P. aeruginosa.
Therefore, we were not able to use those to create isogenic
pairs. Furthermore, genetic manipulation of these clinical isolates
proved to be difficult, as these strains were not universally
amenable to the creation of isogenic mutants via oligonucleotide
recombination. Nonetheless, it is worth nothing that the strains
evaluated in this study were carefully selected to represent a
broad range of characteristics such as varying degrees of FQ
resistance, virulence, and clinical outcomes. While the limited
number of strains evaluated in this study may not necessarily
represent the genetic variability present among all exoU and
exoS clinical strains, strain-specific differences in fitness effects
were observed even among strains with the same exoU or exoS
genetic background, though the trend observed appears to follow
similar pattern for strains with the same exoU or exoS genetic
background.
Understanding the fitness costs of antibiotic resistance
and possibilities of compensation for these costs is essential
for rationally combating the problem of antibiotic resistance.
Importantly, this study outlines a useful model with the creation
of isogenic clinical strains for investigating the biological costs of
resistance in a medically important pathogen and can be applied
to other drug-organism pairs.
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